Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies

BACKGROUND: Furmonertinib (AST2818) is a brain penetrant pan-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both EGFR sensitizing mutations and T790M mutation. We report the pooled central nervous system (CNS) efficacy data of furmonertinib in patients with EGFR T7...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xingsheng, Zhang, Shucai, Ma, Zhiyong, Feng, Jifeng, Wu, Lin, Lv, Dongqing, Zhou, Jianying, Zhang, Xiaodong, Liu, Li, Yu, Qitao, Liao, Wangjun, Zhang, Yiping, Wang, Xiang, Cheng, Ying, Niu, Hongrui, Wang, Ziping, Wang, Dong, Huang, Cheng, Liu, Chunling, Zhao, Hui, Feng, Jian, Li, Jingzhang, Ying, Kejing, Yang, Nong, Qin, Shukui, Hu, Jie, Liu, Fei, Jiang, Yong, Ge, Nan, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148399/
https://www.ncbi.nlm.nih.gov/pubmed/37118803
http://dx.doi.org/10.1186/s12916-023-02865-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148399/
https://www.ncbi.nlm.nih.gov/pubmed/37118803
http://dx.doi.org/10.1186/s12916-023-02865-z

Ejemplares similares